Prognosis
J&J’s Covid Shot Restricted by FDA on Rare Clotting Disorder
- Shot has been used most in low-income countries, remote areas
- Pfizer and Moderna produce the shot of choice, see wider use
This article is for subscribers only.
Johnson & Johnson’s Covid-19 vaccine was limited to use only in U.S. adults for whom other shots aren’t appropriate after an investigation of rare and potentially deadly clotting disorder that occurs in some recipients.
The Food and Drug Administration limited the use of the vaccine to people 18 and older for whom other shots aren’t accessible or clinically appropriate, and those who would otherwise not get immunized against the virus. J&J’s single-shot vaccine has been noted for its convenience compared to two-shot vaccines, especially in remote areas and in populations like the homeless who may be difficult to give repeat immunizations.